
|Articles|April 15, 2006
More study needed before combination therapies for AMD accepted
Baltimore?Photodynamic therapy (PDT) has been the mainstay of treatment for choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD) until recently when combination therapies (PDT and anti-vascular endothelial growth factor [VEGF]) agents started to be explored.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
3
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
4
AAO 2025: Diana Do, MD, reviews the real-world use of aflibercept 8 mg
5